{"preliminary_commentary":{"by_channel":{"x_thread":22,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04722848\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["ponatinib","blinatumomab"]],"indication":"newly diagnosed adult Ph+ ALL","name":"GIMEMA ALL2820","nct_id":"NCT04722848","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=gimema-all2820-nct04722848. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"patients will receive induction with ponatinib followed by at least 2 cycles of blinatumomab","label":"Ponatinib+Blinatumomab","type":"EXPERIMENTAL"},{"description":"patients will receive a combination of imatinib and chemotherapy.","label":"Chemotherapy+Imatinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-09","type":"ESTIMATED"},"conditions":["Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)","ALL, Adult","Philadelphia-Positive ALL"],"enrollment":{"count":236,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ponatinib + Blinatumomab","otherNames":[],"type":"DRUG"},{"name":"Chemotherapy + Imatinib","otherNames":[],"type":"DRUG"}],"last_update":"2025-01-23","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","official_title":"Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment With Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of patients who are event-free","timeFrame":"at 5 months"}],"references":[{"citation":"Chiaretti S, Piciocchi A, Skert C, Leoncin M, Borlenghi E, Cattaneo C, Di Trani M, Elia L, Almici G, Cardinali D, Kaiser F, Lussana F, Fiumara PF, Maugeri C, Alati C, Martino M, Ansuinelli M, Lucco Navei G, Mattei D, Soddu S, Messina M, Marino MR, Mancini V, Chiusolo P, Scappini B, Martelli MP, Salutari P, Cerrano M, Serio B, Cucca A, Luppi M, Pochintesta L, Pasciolla C, Romani C, Mosna F, Bonifacio M, Tanasi I, Fracchiolla NS, Bocchia M, Imbergamo S, Califano C, Nunziata GR, Annunziata M, Mule A, Zappasodi P, Mastaglio S, Butera S, Della Porta MG, Porretto F, Lunghi M, De Bellis E, Todisco E, Basilico CM, Fazi P, Rambaldi A, Bassan R, Foa R; GIMEMA Investigators. Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL. N Engl J Med. 2026 Oct 15;395(15):1483-1494. doi: 10.1056/NEJMoa2606208.","pmid":"42874102","type":"DERIVED"}],"start_date":{"date":"2021-09-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL","url":"https://clinicaltrials.gov/study/NCT04722848"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/gimema-all2820-nct04722848"}